LP250850-7
Certolizumab Ab
Active
Description
Antibodies to certolizumab were detected in about 22% of patients during a 7-year clinical trial of patients with Crohn's disease. Approximately 22% of antibody-positive patients had transient antibodies, and the rest had persistent anti-certolizumab antibodies. Those with persistent antibodies had lower plasma certolizumab concentration and drug efficacy compared to those with transient antibodies as well as those patients who were antibody-negative. PMID: 28410341 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Certolizumab Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2017-05-09
- Construct for LOINC Short Name
- Certolizumab Ab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP250850-7
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright